ExRobotics

Formic aims to increase the collective output of humanity by making automation deployments trivial and easy.

Pitlane Ops builds the verification layer for robotics

Puralink provides autonomous robots for pipe inspection, mapping, and repair.

Dyna Robotics develops advanced robotic manipulation models to automate repetitive and stationary tasks.

Raion Robotics manufactures walking robots for industrial use.

Forge Robotics is an intelligent automation that operates like a human but scales like a machine.

Icarus Robotics, the business, is developing a robotic labour force for space utilising embodied artificial intelligence (AI).

Hive Robotics is developing scalable, cutting-edge technology designed to safely and securely command, control, and connect etc.

Rendezvous Robotics constructs space infrastructure.

Flywheel AI converts existing excavators so contractors can operate them remotely for safety and productivity.

ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.

uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. Our first product, Glybera, was approved by the European Commission in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease. We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations.